BUSINESS
Fujifilm, Australian Startup Join Hands for Contract Manufacturing of iPS Cell-Derived Regenerative Medicine Products
Fujifilm said on September 30 that it has entered into a basic agreement with Cynata Therapeutics to undertake the contract manufacturing of the Australian biotech’s iPS cell-derived regenerative medicine products. In line with this, the Japanese company will hand back…
To read the full story
Related Article
- Fujifilm Grabs Rights to Cynata’s Cell Therapy for GVHD
September 18, 2019
BUSINESS
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Mochida Files in Japan for PAH Drug Tyvaso DPI
May 1, 2026
- Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
May 1, 2026
- 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
May 1, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





